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Alzheimer’s disease is characterized by abnormal elevation of Ab peptide and abnormal hyperphosphoryla-
tion of the tau protein. The ‘‘amyloid hypothesis,’’ which is based on molecular defects observed in
autosomal-dominant early-onset Alzheimer’s disease (EOAD), suggests a serial model of causality, whereby
elevation of Ab drives other disease features including tau hyperphosphorylation. Here, we review recent
evidence from drug trials, genetic studies, and experimental work in animal models that suggests that an
alternative model might exist in late-onset AD (LOAD), the complex and more common form of the disease.
Specifically, we hypothesize a ‘‘dual pathway’’ model of causality, whereby Ab and tau can be linked by
separate mechanisms driven by a common upstream driver. This model may account for the results of recent
drug trials and, if confirmed, may guide future drug development.Introduction
Approximately 80 years after Alois Alzheimer described amyloid
plaques and neurofibrillary tangles in the brain of a demented
patient, the constituents of these hallmark histological features
were finally isolated. Ab peptide, a cleaved product of the
amyloid precursor protein (APP), turned out to be the core bio-
chemical element of plaques (Glenner and Wong, 1984), while
hyperphosphorylated tau, a microtubule binding protein, was
at the core of tangles (Grundke-Iqbal et al., 1986). Once isolated,
an inevitable, and for many years intractable, debate ensued
over whether Ab and tau abnormalities were linked, and whether
either represented an upstream pathogenic cause driving the
disease.
Remarkably, mutations in both genes encoding APP and tau
were found to cause dementing illness, and characterizing the
clinical syndromes and molecular effects of these mutations
informed this debate. Mutations in APP, which accelerate Ab
production, were found to underlie some cases of a monogenic
form of the disease, early-onset Alzheimer’s disease (EOAD)
(Goate et al., 1991). Although extremely rare, EOAD recapitulates
the histological profile of plaques and tangles, and the disease’s
clinical phenotype characterized by hippocampal-predominant
dysfunction and dysfunction in other neocortical sites. In con-
trast, mutations in the gene encoding tau, although found to
cause tau hyperphosphorylation, do not lead to AD. Rather,
these mutations result in a different type of dementia, fronto-
temporal dementia (FTD) (Hutton et al., 1998), which, as
indicated by its name, is characterized by frontal-predominant
dysfunction. Moreover, FTD is histologically distinct from AD in
that it is characterized by tangles that occur first in extrahippo-
campal sites, and most importantly, the brain is devoid of
plaques. Further clarifying the debate, other disease-causing
mutations of EOAD were found in presenilin1 and 2 (Levy-Lahad
et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995), and
these mutations have a primary effect on Ab processing and
plaque formation.534 Neuron 60, November 26, 2008 ª2008 Elsevier Inc.This series of genetic and experimental findings form the basis
of the ‘‘amyloid hypothesis’’ (Hardy and Selkoe, 2002; Tanzi and
Bertram, 2005). This hypothesis proposes a serial model of cau-
sality, in which elevation of Ab is the prime pathogenic driver,
leading to tau hyperphosphorylation and other histological and
clinical features of AD (Figure 1). Because EOAD and late-onset
AD (LOAD) phenocopy each other clinically and histologically,
the amyloid hypothesis—although based on molecular defects
isolated in EOAD—was plausibly proposed to underlie all forms
of the disease.
Since the amyloid hypothesis was first formulated over
15 years ago, two developments informing its relationship to
LOAD have occurred. First, a crop of amyloid-reducing pharma-
cological agents has been successfully developed, allowing
assumptions of the hypothesis to be tested in LOAD patients.
Although, as discussed below, many factors can influence the
results of human drug trials, it is nevertheless newsworthy that
to date the results of these studies have been largely disappoint-
ing. Second, genetic and molecular investigations into LOAD
itself have uncovered a separate set of molecular defects whose
mechanisms of action suggest that additional models linking Ab
and tau are at least biologically plausible.
Although inconsistencies exist within the wide range of clinical
and experimental studies related to LOAD, we believe that as
a whole there is currently sufficient evidence to hypothesize an
alternative ‘‘dual pathway’’ linking Ab and tau abnormalities. Spe-
cifically, as developed here, we hypothesize that common up-
stream drivers causebothelevation in Aband tau hyperphosphor-
ylation through independent but parallel mechanisms (Figure 1).
Notably, this alternative model is not presented as a refutation
of the amyloid hypothesis; disease-causing mutations in APP
and subsequent studies in animal models (reviewed in Duff,
2001) leave little doubt that the serial model can underlie the dis-
ease in certain cases. Rather, the hypothesized dual pathway
model suggests an additional mechanism linking Ab and tau in
LOAD, which if confirmed has important therapeutic implications.
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According to the amyloid hypothesis, a pharmacological agent
that reduces brain Ab levels should act as an effective drug
against the disease. Of the peptide’s two variants, Ab40 and
Ab42, the latter is thought to be more pathogenic, and decreas-
ing its production or increasing its clearance has motivated drug
development. Guided by this rationale, a number of pharmaco-
logical agents have been developed and have been evaluated
in LOAD patients. Ab42 immunization is perhaps the most excit-
ing pharmacological development (Wisniewski and Konietzko,
2008), and two methods have been evaluated in patients: active
immunization, in which endogenous anti-Ab42 antibodies are
generated by injecting patients with the peptide itself, or passive
immunization achieved by directly injecting patients with exoge-
nously generated anti-Ab42 antibodies. Preclinical studies in
mouse models have established that both immunization regi-
mens significantly reduce soluble and insoluble forms of brain
Ab. A third agent developed and tested in LOAD patients is
tarenflurbil (Flurizan, Myriad Pharmaceuticals), which acts by
decreasing the production of Ab42 (Aisen, 2008). Finally, trami-
prosate (Alzhemed, Neurochem Inc.) is a fourth pharmacolog-
ical agent tested in LOAD patients and worth mentioning (Aisen
et al., 2007). While its proposed mode of action is blocking Ab
aggregation, not reducing Ab per se, its development was in
part based on the amyloid hypothesis.
Although at different stages of development, to date, these
human clinical trials have been largely disappointing. There
are, of course, many reasons for failures in human drug trials
and, in any case, negative results do not necessarily refute the
serial model underlying the amyloid hypothesis. It is easy to
defend the amyloid hypothesis by invoking the plausible
assumption that Ab acts as a ‘‘trigger’’ of downstream tau hyper-
phosphorylation, so that once initiated, pathology might
progress even when Ab levels are significantly reduced. Because
AD has a long incubation period, it is possible therefore that the
Figure 1. Two Hypothesized Models Linking
Core Features of Alzheimer’s Disease
The amyloid hypothesis assumes a serial model of
causality, whereby abnormal elevations in Ab drive
tau hyperphosphorylation and other downstream
manifestations of the disease. According to the dual
pathway hypothesis, Ab elevations and tau hyper-
phosphorylation can be linked by separate mecha-
nisms driven by a common upstream molecular
defect.
Ab-reducing agents tested in LOAD patients
were ineffective simply because they were
given too late, when secondary events like
tau hyperphosphorylation had already begun.
In this regard, one recent study docu-
menting the long-term effects of active
Ab42 immunization is worth highlighting
(Holmes et al., 2008). Although the phase I
trial was halted because active immunization
caused lethal menigoencephalitis in a small
number of subjects, this study followed
a group of subjects free of the drug’s untoward effects prospec-
tively for over a 6 year period. In fact, during this period, eight
consenting patients came to autopsy, allowing the rare opportu-
nity to document drug efficacy by postmortem analysis. In clini-
cal assessments, the dozens of treated patients were compared
to a placebo group (AD patients who received a low dose of the
peptide that did not generate an immune response), and the
results revealed no significant effect of immunization on any clin-
ical measure. Because no subject in the placebo group came to
autopsy, the postmortem assessment was performed by com-
paring the brains’ of the treated group to an age-matched group
of AD brains harvested from unimmunized patients. In agree-
ment with preclinical animal studies, immunized patients were
found to have significantly lower levels of Ab. Remarkably,
correlating with degree of the immune response, two patients
with the highest levels of anti-Ab antibodies were found to
have a near complete reduction of Ab pathology.
Although the results are based on a small and potentially
biased sample, this particular study is notable for its long
6 year followup (most clinical studies are 18 months or less)
and the histological evidence documenting the drug’s Ab-reduc-
ing effects. Because of these features, the cognitive profile of
clinical decline and the anatomical pattern of pathology reported
in the study are extremely informative. At baseline a number of
the treated subjects were only mildly affected, as indicated, for
example, by a modified mini-mental exam score above 20 (max-
imum score = 30). Nevertheless, nearly all the subjects who
came to autopsy had a profound decline in their cognition over
the 6 year period. Seven out of the eight patients were found
to have a mini-mental exam score of 0 prior to death, indicating
that the patients were so thoroughly impaired that they could not
even engage in a simple cognitive assessment.
The clinical progression of AD, as exemplified in this study,
reflects two underlying events: the worsening of AD pathology
within a targeted brain region, and the anatomical spread ofNeuron 60, November 26, 2008 ª2008 Elsevier Inc. 535
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(Braak et al., 2006) (Figure 2). The relatively long duration of the
immunization study and the documented pattern of cognitive de-
cline strongly suggest that both events occurred in the immu-
nized subjects. This interpretation agrees with the observation
that at death all treated subjects had tau pathology heavily dis-
seminated across the cortex, as evidenced by a Braak stage of
VI in seven out of the eight subjects (the eighth subject, who
died 4 months after initiation of treatment, had a Braak stage of V).
The Braak staging system semiquantifies the degree of tau
hyperphosphorylation and/or aggregated tangles within a given
region (Braak et al., 2006), and, more importantly, the anatomical
distribution of tau pathology across the brain. While imperfect,
the Braak staging system is considered a good anatomical
map of AD-related brain dysfunction, and in general agrees
with neuropsychological and imaging indicators of disease
(Whitwell et al., 2007). During early stages of the disease, Braak
stage I–II, dysfunction is observed primarily in the archiocortex of
the entorhinal area, and then, during Braak stage III–V, spreads
to tertiary and secondary neocortex within the temporal, occipi-
tal, and frontal lobes. Typically, it is only during the last stage
(Braak et al., 2006), Braak stage VI, that AD pathology spreads
to the primary motor and sensory cortex (Figure 2). While there
is some mismatch between anatomical patterns of plaques
and tangles, maps of plaque burden agree that primary cortex
is typically affected only late in the disease process (Braak and
Braak, 1991). Notably, most studies would suggest that based
on their mini-mental exam scores, the immunized subjects
would most likely be at a Braak stage no greater than IV–V
(Jack et al., 2002) at baseline. Although there are rare exceptions
to this rule (Knopman et al., 2003), it is nevertheless fair to as-
sume that the primary cortex of the treated group would have
been relatively free of tau abnormalities prior to receiving treat-
ment (Figure 2).
The ‘‘trigger’’ idea invoked to defend the serial model of the
amyloid hypothesis could have easily explained clinical progres-
sion in the immunized subjects had the evidence suggested that
Figure 2. Anatomical Progression of Alzheimer’s Disease
In the typical progression of Alzheimer’s disease, primary motor and sensory
cortex are affected in the last stage of the disease, Braak stage VI. During
the last stage of disease, the primary visual cortex is characterized by tau hy-
perphosphorylation (as shown using anti-phospho-tau antibodies), neurofibril-
lary tangles, and amyloid plaques (adapted from Braak et al., 2006 with kind
permission of Springer Science/Business Media).536 Neuron 60, November 26, 2008 ª2008 Elsevier Inc.AD pathology worsened within tertiary or secondary neocortex.
However, we believe that the serial model of causality, even
with the trigger caveat, is strained by the evidence suggesting
that tau hyperphosphorylation spread throughout the brain,
reaching as far as primary cortex.
Besides the issue of timing, a range of additional possibilities
have been generated to try and explain the incontrovertibly neg-
ative results of this study—in the paper itself (Holmes et al., 2008)
and in an accompanying editorial (St George-Hyslop and Morris,
2008). For example, because Ab peptides aggregate to form
dimers and oligomers of different sizes, the possibility was raised
that the ‘‘truly’’ neurotoxic form of Ab might not have been re-
duced. Additionally, the small number of subjects and the high
dropout rate were flagged as potential sources of bias, although,
even if considered just a descriptive study, case-studies are
typically sufficient to test a ‘‘strong version’’ of the hypothesis.
Indeed, the two patients who had a nearly complete reduction
of Ab pathology nevertheless progressed from a baseline mental
status score in the low 20 s to 0.
Post hoc explanations are always possible. Nevertheless, we
believe that the results from this and other drug studies, at the
very least, open up the possibility that an alternative model of
causality linking Ab and tau in LOAD is worthy of consideration.
Dual Pathways Linking Ab and Tau
As mentioned, the amyloid hypothesis emerged out of molecular
defects found to be causative in EOAD, though not necessarily
in LOAD. In contrast to EOAD, LOAD is a complex, not a mono-
genic, disorder. Indeed, numerous molecular pathways have
been linked to LOAD, and consistent with its etiological com-
plexity, it is often difficult to confirm and validate whether a defec-
tive pathway associated with LOAD plays a causative role.
Nevertheless, even without the equivalent of ‘‘Koch’s postu-
lates,’’ the pathogenic likelihood of an implicated pathway is
increased if it has some degree of genetic confirmation, if
expressing defective elements of the pathway in animal models
phenocopies features of the disease, and if specific mechanisms
linking the pathway to Ab or tau have been established.
Although a number of molecular pathways implicated in LOAD
meet these pathogenic criteria, our goal is not to provide an
exhaustive review. Rather, in order to establish the plausibility
of an alternative model, we will focus on a select few simply to
demonstrate the principle that mechanisms exist by which Ab
and tau can be regulated by single upstream drivers. When gen-
erating a testable hypothesis in complex disorders, we believe
that some, not all, molecular defects are sufficient for establish-
ing biological plausibility. More than just meeting some of these
pathogenic criteria and illustrating the plausibility of the model,
the three molecular pathways we will focus on have the addi-
tional benefit of being mechanistically interconnected. As we
emphasize below, each molecular pathway has its own limita-
tions and weaknesses, so that the overall model (Figure 3) is
strengthened when viewed as a whole.
APOE
Of the molecular factors linked to LOAD, apolipoprotein E
(APOE) genotype is the one that is most robustly implicated in
LOAD pathogenesis, although it has been shown to influence
EOAD as well (Pastor et al., 2003). The APOE gene encodes
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genotype was found to profoundly increase LOAD risk com-
pared with the other variants (Corder et al., 1993; Saunders
et al., 1993).
Although inconsistencies do exist, several postmortem studies
have shown that inheritance of the APOE4 genotype is associated
with an increase in both plaque and tangle load (as shown and re-
viewed in Tiraboschi et al., 2004). As a corollary in living subjects,
cerebral spinal fluid (CSF) studies have also found an association
between APOE4 genotype and both Ab (Galasko et al., 1998;
Sunderland et al., 2004) and phospho-tau levels (Glodzik-Soban-
ska et al., 2007; Golombowski et al., 1997). Although FTD caused
by tau mutations does not appear to be robustly influenced by
APOE4 genotype (Houlden et al., 1999; Pickering-Brown et al.,
2000), it is plausible that the mutations override the impact of
APOE4, similar to the lack of APOE4’s effect in AD patients with
presenilin mutations (Van Broeckhoven et al., 1994). In support
of this, in one study relatively young nondemented individuals
(mean = 44), unlikely to have plaques or Ab pathology, were found
to have more tangles in the entorhinal area if they were APOE4
positive (Ghebremedhin et al., 1998).
Experimental confirmation of APOE’s impact on the patholog-
ical pathways seen in AD comes from a wide range of cell and
animal model studies showing that APOE can affect both Ab/
plaque accumulation (Bales et al., 2002; DeMattos et al., 2004;
Dodart et al., 2005) and tau/tangle accumulation (Bi et al., 2001;
Brecht et al., 2004; Genis et al., 2000; Harris et al., 2003, 2004;
Huang et al., 2001; Ohkubo et al., 2003; Tesseur et al., 2000a,
2000b). Nevertheless, as will be reviewed below, current work
in animal models provides a stronger link between APOE4
and Ab/plaque accumulation. Importantly, a range of findings
Figure 3. Molecular Defects that Support a Dual Pathway
Hypothesis in Late-Onset Disease
Examples of dual pathways linking elevations of Ab peptide and tau hyper-
phosphorylation through common upstream molecular defects implicated in
late-onset Alzheimer’s disease.suggests that APOE affects Ab and tau through independent
mechanisms (Figure 3).
Although a number of mechanisms linking APOE4 to Ab have
been proposed (Ye et al., 2005), the dominant view suggests that
APOE released from astroglia plays a role in clearing Ab from the
extracellular brain parenchyma, and that compared to other iso-
forms, APOE4 causes increased Ab by decreasing its clearance
(Bales et al., 2002; DeMattos et al., 2004; Fagan et al., 2002).
From an anatomical perspective is it worth noting that neurons
of the entorhinal cortex send their axons to the molecular layer
of the dentate gyrus, a layer observed to have high concentration
of Ab deposition (Reilly et al., 2003), and severing these axons
causes decreased deposition (Buxbaum et al., 1998; Lazarov
et al., 2002). A number of studies have documented that
APOE4 causes increased deposition of Ab in this outflow site
of the entorhinal cortex (Irizarry et al., 2000a, 2000b).
A separate and distinct group of mechanisms has been
proposed to link APOE with tau hyperphosphorylation (Brecht
et al., 2004; Harris et al., 2003; Huang et al., 2001), but one in
particular has been supported by a growing number of studies.
Specifically, a wide range of studies have established a link
between APOE and glycogen synthase kinase 3 (GSK3), one of
the main kinases that phosphorylates tau (Hong et al., 1997;
Lovestone et al., 1996) (Figure 3). For example, studies have
shown that APOE regulates GSK3 activity (Hoe et al., 2006; Oh-
kubo et al., 2003), that APOE4 has the greatest effect in activat-
ing GSK3 (Cedazo-Minguez et al., 2003), and that compared with
other isoforms, APOE4 is least likely to bind tau at GSK3 binding
sites (Gibb et al., 2000). Because most of these studies were per-
formed in cell culture, these effects are likely to have occurred
independent of the effect APOE has on the extracellular concen-
trations of Ab in the intact brain.
Further strengthening the link between and APOE and GSK3,
several mechanisms have been postulated to account for these
empirical observations. One relies on the suggestion that APOE
might bind tau (Huang et al., 1995), thereby blocking phosphor-
ylation sites. Because it appears to bind less avidly than other
isoforms (Strittmatter and Roses, 1995), studies suggest that
APOE4 increases the likelihood of GSK3-mediated tau hyper-
phosphorylation (Gibb et al., 2000). An unresolved issue,
however, is how much APOE is actually expressed in neurons,
and whether APOE or its fragments are in the correct intracellular
compartment to bind endogenous tau.
A more compelling mechanism linking APOE, GSK3, and tau
phosphorylation does not necessarily require neuronal expres-
sion of APOE or a direct interaction with tau; rather, it is based
on cell surface LDL and LDL receptor-related proteins (LRPs)
to which APOE binds (Beisiegel et al., 1989; Herz and Bock,
2002). Although other members of this family of receptors might
play a role (Herz and Bock, 2002; Zilberberg et al., 2004), LRP5
and LRP6 are the ones that most directly regulate GSK3 activity,
as part of the wnt signaling pathway (De Ferrari and Moon, 2006).
Studies suggest that APOE directly binds and interacts with
LRP5 (Kim et al., 1998; Magoori et al., 2003), although a func-
tional relationship between APOE and LRP6 has also been sug-
gested (Caruso et al., 2006). At the same time, we should be
point out that many experiments use poorly lipidated forms of
APOE. LRP5 and LRP6 together with members of the frizzledNeuron 60, November 26, 2008 ª2008 Elsevier Inc. 537
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tracellular glycoprotein wnt binds. GSK3 is the dominant kinase
that mediates the intracellular wnt signaling pathway, such that
kinase activity is suppressed when wnt binds its receptor com-
plex (De Ferrari and Moon, 2006). A recent study found that com-
pared with other APOE isoforms, APOE4 inhibits this pathway via
LRP5 and LRP6, leading to an upregulation of GSK3 activity
(Caruso et al., 2006). Furthermore, a recent genetic finding in
LOAD patients suggests a genetic link between APOE and
LRP6 (De Ferrari et al., 2007) and provides evidence that the
identified LRP6 genetic variant affects wnt signaling via in-
creased GSK3 activity. Additional indirect evidence linking
APOE, GSK3, and tau comes from an interesting gene expres-
sion study showing that APOE and GSK3 are both differentially
expressed in the entorhinal cortex (Liang et al., 2007), which,
as mentioned, is the site where tau pathology begins.
Nevertheless, as previously stated, on balance the current
evidence establishes a stronger link between APOE4 and Ab/
plaques. In particular, we acknowledge that although in vitro
studies indicate that tau phosphorylation can be mediated by
GSK3 in the wnt signaling pathway (Asuni et al., 2006;
Mercado-Gomez et al., 2008; Mi et al., 2006; Scali et al., 2006),
and APOE4 mice do show some degree of tau hyperphosphor-
ylation (Brecht et al., 2004; Harris et al., 2003; Huang et al.,
2001), in vivo evidence documenting an APOE-mediated effect
on wnt signaling and tau phosphorylation is still lacking.
GSK3
Several lines of evidence have implicated GSK3 in LOAD, inde-
pendent of its association with APOE, although a recent study
has also implicated GSK3 in FTD (Schaffer et al., 2008). Studies
linking GSK3 to LOAD include human studies showing that
active-state GSK3 is bound to tangles in the human entorhinal
area and other brain regions (Pei et al., 1999; Shiurba et al.,
1996), and studies in animal models showing that overexpress-
ing GSK3 causes tau hyperphosphorylation and hippocampal
dysfunction in transgenic mice (Engel et al., 2006; Hernandez
et al., 2002; Lucas et al., 2001) and enhanced tau pathology in
transgenic flies (Jackson et al., 2002).
In addition, a number of genetic studies have either directly
(Mateo et al., 2006) or indirectly (De Ferrari et al., 2007) linked
GSK3 activity to LOAD. As mentioned, besides APOE4, all other
genetic findings linked to LOAD have either small effect sizes or
have not been universally found in all studies. Because a genetic
variant with a small effect size might nevertheless be pathogenic
in complex disorders, as a general point, when evaluating the val-
idity of genetic findings in LOAD a number of questions should be
considered. In how many independent populations has the link
been found? Because most studies are based on linkage analy-
sis, has an actual ‘‘functional’’ polymorphism in the gene been
isolated? Is there is a plausible mechanism suggesting how the
genetic defect can play a pathogenic role in the disease?
Based on current knowledge, we believe that the genetic evi-
dence indirectly linking GSK3 activity to LOAD is more compel-
ling than the limited studies that suggest variance in the GSK3
gene itself (Mateo et al., 2006). In the recent study that estab-
lished a link between genetic variance in LRP6 and LOAD (De
Ferrari et al., 2007), this finding was replicated in three separate
populations, and a functional polymorphism was identified that538 Neuron 60, November 26, 2008 ª2008 Elsevier Inc.increased GSK3 activity through the wnt signaling pathway.
Interestingly, genetic variance in T-catenin (Bertram et al.,
2007), which is also part of the wnt signaling pathway, has also
been linked to LOAD. Additionally, it is worth mentioning that
presenilin itself is also part of the wnt signaling pathway indirectly
affecting GSK3 activity (Kang et al., 2002; Koo and Kopan, 2004).
As discussed above, there is no question that increasing GSK3
activity will lead to hyperphosphorylation of tau (Figure 3). In
a parallel fashion, however, a growing number of studies suggest
that GSK3 overactivity might also lead to elevation of Ab, likely by
affecting the enzymatic processing of APP (Phiel et al., 2003; Su
et al., 2004) (Figure 3). GSK3 has two isoforms—GSK3a and
GSK3b—and currently the most compelling evidence implicates
GSK3a activity in APP processing (Phiel et al., 2003), although
evidence for GSK3b also exists (Su et al., 2004). In any case,
the high sequence homology between the two isoforms suggest
functional overlap (Woodgett, 2001), and more importantly, there
is now growing evidence to suggest that both isoforms are reg-
ulated by similar upstream pathways including wnt signaling
(Asuni et al., 2006).
Retromer
The retromer sorting pathway is made up of multimeric coat
complex, which transports a transmembrane retromer-binding
receptor (Seaman, 2005). The mammalian complex is made up
of VPS35, VPS26, VPS29, and SNX1/2, all highly expressed in
the brain (Haft et al., 2000). Mouse studies have shown that
elements of the retromer complex are differentially expressed
in the hippocampal formation (Lein et al., 2007), and a human
study found that within the hippocampal formation, VPS35 and
VPS26 are differentially expressed in the entorhinal cortex
(Small et al., 2005). Among the many possible candidates, two
VPS10-containing proteins, sorLA and sortilin, have been shown
to act as retromer-binding receptors in neurons (Muhammad
et al., 2008). In yeast, in which the retromer sorting pathway
was first described, VPS10 acts as a major retromer-binding
receptor, suggesting functional homology.
Converging lines of evidence have implicated the retromer
sorting pathway in LOAD: (1) studies in human brain tissue
have found deficient levels of VPS35, VPS26, and sorLA
(Scherzer et al., 2004; Small et al., 2005). (2) Studies in animal
models have shown that deficiencies in VPS35 and VPS26 sim-
ilar to those found in LOAD patients cause hippocampal dys-
function (Muhammad et al., 2008). (3) Studies in animal models
and cell culture have shown that deficiencies in VPS35,
VPS26, and sorLA cause an elevation in Ab and Ab aggregates
(Andersen et al., 2005; Muhammad et al., 2008). (4) Studies in
human patients have shown that genetic variance in sorLA
(also called sorl1) is linked to LOAD (Rogaeva et al., 2007).
In evaluating the genetic link, it should be emphasized that it
has now been replicated in most (though not all) subsequent
studies, and according to Alzgene (www.alzforum.org/res/com/
gen/alzgene/default.asp), positive linkage has been found in 13
out of 20 populations. Additionally, because sorLA could poten-
tially be involved in numerous biological functions, the primary
study that first reported linkage established that sorLA is indeed
part of the retromer sorting pathway—showing, for example, that
VPS35 binds sorLA and that downregulating either sorLA or
VPS26 results in similar increases in Ab (Rogaeva et al., 2007).
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sorLA protein has been reliably observed in a large number of
LOAD brains (Sager et al., 2007; Scherzer et al., 2004), more
commonly than would be expected from this rare genetic variant.
This concern is partly allayed by a recent finding showing that
a primary reduction in VPS35 leads to secondary reductions in
sorLA (Nielsen et al., 2007), as would be expected for a retro-
mer-binding receptor (Seaman, 2005). Thus, it is likely that sorLA
deficiency observed in LOAD is driven in part by the genetic
variant and secondarily by other factors that cause deficiencies
in the retromer complex itself. Taken as a whole, we conclude
that the evidence implicating the retromer sorting pathway in
LOAD is compelling, even though the genetic evidence has
a relatively weak effect size.
As mentioned, there is now clear evidence documenting that
deficiencies in elements related to the retromer sorting pathways
will similarly elevate Ab. Because sorLA binds APP (Andersen
et al., 2005; Spoelgen et al., 2006), the plausible mechanism to ac-
count for this effect is that defects in the retromer pathway will
cause a mis-sorting of APP, increasing the resident time of APP
within a given membrane compartment, thereby increasing the in-
teraction between APP and its cleaving enzymes and leading to
accelerated Ab production (Small and Gandy, 2006) (Figure 3).
Interestingly, a separate and growing group of studies has
established that the retromer sorting pathway also plays a role
in the wnt signaling pathway. Because, to date, this observation
is based on eight separate studies (Belenkaya et al., 2008; Cou-
dreuse et al., 2006; Franch-Marro et al., 2008; George et al.,
2007; Pan et al., 2008; Port et al., 2008; Prasad and Clark,
2006; Yang et al., 2008) (as reviewed in (Eaton, 2008) using
a range of animal and cell models, the relationship between
the retromer sorting pathway and wnt signaling is considered be-
yond dispute. After transcription and posttranscriptional modifi-
cation in the endoplasmic reticulum and golgi apparatus, wnt
binds and forms a complex with a transmembrane chaperone
protein called wntless (WLS) in the transgolgi network (TGN)
(Hausmann et al., 2007). The bound complex is then trafficked
to the cell surface where wnt dissociates from WLS and is
secreted into the extracellular space. The membrane-bound
WLS is then endocytosed, and in the endosome WLS binds
the retromer complex, which transports WLS back to the TGN.
In the face of retromer deficiency, WLS, like sorLA, is sorted to
the lysosome for degradation.
Thus, just as with sorLA, retromer deficiency causes a reduc-
tion in WLS, with the end result being decreased wnt secretion;
a decrease in activation of the wnt receptor complex, frizzled,
and LRP5 and LRP6; and an upregulation of GSK3 activity
(Figure 3). Although not yet demonstrated empirically, we
hypothesize that the upregulation of GSK3 activity caused by
retromer deficiency should result in tau hyperphosphorylation
(Figure 3), independent and in parallel of its established effects
on APP processing.
Therapeutic Implications
As mentioned, the dual pathway hypothesis is offered as an ad-
ditional model of causality, not as a replacement of the amyloid
hypothesis. In fact, because Ab itself has been found to interact
with wnt receptors (Chacon et al., 2008; Magdesian et al., 2008),components outlined in Figure 3 can be coopted by the amyloid
hypothesis to link Ab to tau hyperphosphorylation in a serial
manner. However, in the dual pathway scenario, reducing Ab
alone, although predicted to have some effect, might be insuffi-
cient to completely block tau hyperphosphorylation and subse-
quent neurodegeneration. From a therapeutic perspective, if
the dual pathway hypothesis is validated, diagnosing AD
patients at the molecular level would become important, to
determine whether the serial or dual pathway model underlies
an individual’s pathophysiology. So, for example, patients with
primary defects in APP processing (mutations, copy number,
etc.) would be predicted to benefit most from Ab reducing
agents, while, according to the model proposed here, patients
expressing the APOE4 genotype or having retromer deficiency
would not.
An important therapeutic implication of the dual pathway
model is that the findings upon which it is based suggest that it
might be plausible to develop drugs that simultaneously target
both Ab and tau. Even among defenders of the amyloid
hypothesis, the recent drug failures have led to the general
acknowledgment that effective therapeutics should target both
abnormalities. The prevailing view is that a mixture of different
drugs will be needed: those that reduce Ab and plaques
and others that reduce tau phosphorylation and tangles. The
observation, as reviewed here, that singular molecular defects
may drive both abnormalities, provides a pharmacological ratio-
nale for searching out and developing single agents that can
ameliorate both core defects of AD.
Conclusions
We believe that clinical findings from a growing number of Ab-
reducing drug trials in LOAD suggest that alternative models link-
ing Ab with tau are worth considering, and molecular findings
related to LOAD provide evidence that an alternative model is
biologically plausible. The specific molecular pathways outlined
here are just exemplars, showing that Ab and tau abnormalities
can be linked through common upstream drivers. We believe
that there are other molecular pathways pathogenic in LOAD
that can act in a similar manner (Geschwind, 2003). Of course,
currently, the dual pathway model is offered only as a working
hypothesis. As is the case for any biologically sound hypothesis,
it can be refuted, confirmed, or modified by future studies in hu-
man patients and animal models.
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